Abstract
Immune checkpoint inhibitors (ICIs) represent a major breakthrough for cancer treatment. However, evidence regarding the use of ICIs in pancreatic cancer (PC) remained scarce. To assess the efficacy and safety of ICIs plus chemotherapy, patients with advanced PC were retrospectively recruited and were treated with either chemotherapy alone or chemotherapy plus ICIs. Patients previously treated with any agents targeting T-cell co-stimulation or checkpoint pathways were excluded. The primary outcome was overall survival (OS). The secondary outcomes were progression-free survival (PFS), overall response rate (ORR) and safety. In total, 58 patients were included (combination, n = 22; chemotherapy, n = 36). The combination group showed a significantly longer OS than the chemotherapy group [median, 18.1 vs 6.1 months, hazard ratio (HR) 0.46 (0.23–0.90), P = 0.021]. The median PFSs were 3.2 months in the combination group and 2.0 months in the chemotherapy group [HR 0.57 (0.32–0.99), P = 0.041]. The combination group and the chemotherapy group had similar ORRs (18.2% vs 19.4%, P = 0.906). All patients who achieved a partial response received a doublet chemotherapy regimen regardless of co-treatment with ICIs. Grade 3 or higher adverse events occurred in 31.8% of the patients in the combination group and in 16.9% of those receiving chemotherapy. Although the incidence of serious treatment-related adverse events was higher in the combination group than in the chemotherapy group, the difference was not significant (P = 0.183). Our findings suggest that the combination of ICIs with chemotherapy is both effective and tolerable for advanced PC. ICIs combined with a doublet chemotherapy regimen might be a preferable choice.
Similar content being viewed by others
Abbreviations
- ASCO:
-
American Society of Clinical Oncology
- ASCO-GI:
-
American Society of Clinical Oncology-gastrointestinal cancer
- CR:
-
Complete response
- DCR:
-
Disease control rate
- ECOG:
-
Eastern Cooperative Oncology Group
- FOLFIRINOX:
-
Fluorouracil/leucovorin plus irinotecan plus oxaliplatin
- GEST:
-
Gemcitabine and S-1 Trial
- HR:
-
Hazard ratio
- ICI:
-
Immune checkpoint inhibitor
- dMMR:
-
Mismatch repair deficient
- mOS:
-
Median overall survival
- mPFS:
-
Median progression-free survival
- MSI-H:
-
Microsatellite instability-high
- ORR:
-
Overall response rate
- PC:
-
Pancreatic cancer
- PR:
-
Partial response
- PS:
-
Performance status
- SD:
-
Stable disease
- TRAE:
-
Treatment-related adverse event
References
Sun DY, Ma JX, Wang JL, Han C, Qian YY, Chen GY et al (2019) Anti-PD-1 therapy combined with chemotherapy in patients with advanced pancreas cancer in a real-world clinical setting. J Clin Oncol 37(15_suppl):e14103 (Abstract)
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
van Roessel S, Kasumova GG, Verheij J, Najarian RM, Maggino L, de Pastena M, International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) et al (2018) TNM staging system in patients with resected pancreatic cancer. JAMA Surg 153:183617
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825
Hammers H, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF et al (2014) Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma. Ann Oncol 25(suppl):iv361–iv362 (abstr)
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920
Heery CR, O’Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M et al (2017) Avelumab for metastatic or locally advanced previously treated solid tumors (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18:587–598
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520
Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S et al (2017) Hypermutation in pancreatic cancer. Gastroenterology 152:68–74
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M et al (2015) Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293
Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US et al (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828–833
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–442
Vonderheide RH, Bayne LJ (2013) Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 25:200–205
Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL et al (2015) Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 3:399–411
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39:74–88
Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13:143–158
Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E et al (2018) Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Investig New Drugs 36:96–102
Borazanci EH, Jameson GS, Board MJ, Ramanathan RK, Korn RL, Caldwell L et al (2018) A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 36(4suppl):abstract358
Renouf DJ, Dhani NC, Kavan P, Jonker DJ, Wei ACC, Hsu T et al (2018) The Canadian Cancer Trials Group PA.7 trial: results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol 36(4suppl):abstract349
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC et al (2012) Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J AM Acad Dermatol 67:1025–1039
Des Jarlais DC, Lyles C, Crepaz N, TREND Group (2005) Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 94:361–366
Di Marco M, Di Cicilia R, Macchini M, Nobili E, Vecchiarelli S, Brandi G et al (2010) Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep 23:1183–1192
Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557
Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N et al (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648
Yoshitomi H, Togawa A, Kimura F, Ito H, Shimizu H, Yoshidome H et al (2008) A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 113:2448–2456
Zhang SH, Liu GF, Li XF, Liu L, Yu SN (2018) Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: a network meta-analysis. J Cell Physiol 233:3352–3374
Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21:15–25
Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215–233
Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ et al (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4013–4905
Plate JM, Plate AE, Shott S, Bograd S, Harris JE (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915–925
Soliman HH (2016) Nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther 10:101–112
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092
Acknowledgements
We thank the patients and their families.
Funding
This work was funded by the National Natural Science Foundation of China [81402552 to Yi Hu, 81672996 to Yi Hu].
Author information
Authors and Affiliations
Contributions
Conception and design: JXM, DYS, SLC and YH. Protocol writing: JXM, DYS, JS, SLC and YH. Data collection: CH, JLW, YYQ, GYC, XYL, PFC, JZ, WSD, SXC, ZZW, XZ and ZCY. Data analysis: JS, JXM and CG. Manuscript writing: JS, JXM, DYS and JLW. Manuscript revisions: CG, YH and SLC. All authors contributed to writing and reviewing the manuscript and approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval and ethical standards
The study was approved by the institutional review board of the People’s Liberation Army General Hospital, Beijing, China (approval number: S2018-144-02). This clinical study was conducted in accordance with the Helsinki declaration and its later amendments.
Informed consent
Because of the retrospective nature of the study, informed consent was waived by the People’s Liberation Army General Hospital, Beijing. This paper does not contain any individual person’s data in any form.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Parts of the data have been published as an abstract at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting which was held during May 31–June 4, in Chicago, IL, USA [1].
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ma, J., Sun, D., Wang, J. et al. Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunol Immunother 69, 365–372 (2020). https://doi.org/10.1007/s00262-019-02452-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-019-02452-3